Intranasal sumatriptan is a selective 5-HT1B/1D receptor agonist that rapidly constricts cranial blood vessels and inhibits neurogenic inflammation in the trigeminovascular system. It provides rapid relief for acute cluster headache attacks by targeting serotonin receptors in the central nervous system and peripheral vasculature, with onset of action typically within 15 minutes of administration.